News Digest / Ticker: CMPS

Ticker: CMPS

07:05am, Thursday, Jul 31, 2025

Compass Pathways Reports Q2 2025 Financials Amid Ongoing Development of COMP360 Psilocybin Treatment

Company Overview: Compass Pathways plc (NASDAQ: CMPS), is a biotechnology company focused on developing its investigational COMP360 psilocybin treatment for mental health disorders, particularly treatment-resistant depression (TRD). Recent Financial Performance: Net Loss: In Q2 2025, the company...

07:01am, Thursday, May 08, 2025

COMPASS Pathways Reports Q1 2025 Financials Amid Progress on Psilocybin Treatment for Depression

COMPASS Pathways plc (NASDAQ: CMPS) has recently reported financial results for the quarter ending March 31, 2025, revealing a strategic focus on its investigational COMP360 psilocybin treatment aimed at addressing treatment-resistant depression (TRD) and potentially other mental health condition...